Roche lands EU Kadcyla approval, ducks EMA criticism

Share this article:

Roche is riding a wave of good news. The company announced Wednesday that the EU greenlighted Kadcyla for HER2-positive breast cancer. The US approved the drug this year, but the OK was accompanied by questions about its viability. The so-called “super Herceptin” was expected to cost around $94,000 for a standard course of treatment, and the approval overlapped just as a pricing standoff between Memorial Sloan-Kettering and Sanofi ended with the drugmaker yielding on price.

The company is also breathing easy-ish because the European Medicines Agency decided that the firm's failure to reveal 80,000 adverse-events reports was no big deal. FiercePharma reports that Roche says the number of unreported AEs was really 23,000 and the EMA says these incidents were not associated with any negative outcomes.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Genentech shift could prove costly for hospitals

Genentech will use specialty distributors rather than wholesalers, hospitals pharmacy directors have learned.

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies